Patent classifications
C07K16/4233
TREATMENT OF OTITIS MEDIA
A method of treating otitis media in a subject is described that includes administering to the subject a therapeutically effective amount of an Actin-Related Protein 2/3 Complex (Arp2/3) inhibitor. The role of Arp2/3 in otitis media was identified using comprehensive proteomic and metabolomic studies of otitis media using the chinchilla model.
Anthropogenic insect-resistant gene and Cry1C toxin idiotype single-chain antibody encoded thereby and application thereof
An anthropogenic insect-resistant gene having a nucleotide sequence represented by SEQ ID NO.1, and a Cry1C toxin idiotype single-chain antibody encoded by said anthropogenic insect-resistant gene and having an amino acid sequence represented by SEQ ID NO.2; the antibody is a β-type and has insecticidal activity, and after expression by the prokaryotic system, the primary culture thereof has binding activity to Cnaphalocrocis medinalis midgut peritrophic membrane specific receptor BBMV; the β-type Cry1C toxin idiotype single-chain antibody of the present invention is obtained without animal immunization, has a short preparation period and small amino acid sequence, and is suitable for large-scale in vitro production. The present invention is an entirely new insect-resistant gene resource, and has significant implications for decreasing the various safety risks associated with the widescale use of existing Bt toxins, substituting Bt toxins in the biocontrol of agricultural pests, and reducing the use of pesticides.
METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE IN COMPANION ANIMALS
The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) in companion animals.
Human-derived insecticidal bt cry toxin mimetic, and design method and application thereof
The present invention provides a human-derived molecularly modified insecticidal protein, and a preparation method and application thereof, and belongs to the field of genetic engineering and biological control. The present invention provides a human-derived molecularly modified insecticidal protein, and the amino acid sequence of the insecticidal protein CCL-CCL_scFv is shown as SEQ ID No. 1. The insecticidal protein CCL-CCL_scFv shows significantly higher affinity with midgut BBMV of Plutella xylostella than Cry1Ab toxin, competes with Cry1Ab and Cry1Ac toxins for binding the midgut BBMV of Plutella xylostella, and is a mimic of Cry1Ab and Cry1Ac toxins. Through Plutella xylostella indoor insecticidal biological activity assay, the insecticidal protein shows a good insecticidal effect, and can effectively replace Cry1Ac or Cry1Ab toxin for biological control of insect pest.
Improved Human-Derived Insecticidal Bt Cry Toxin Mimetic, And Design Method And Application Thereof
The present invention provides a human-derived molecularly modified insecticidal protein, and a preparation method and application thereof, and belongs to the field of genetic engineering and biological control. The present invention provides a human-derived molecularly modified insecticidal protein, and the amino acid sequence of the insecticidal protein CCL-CCL_scFv is shown as SEQ ID No.1. The insecticidal protein CCL-CCL_scFv shows significantly higher affinity with midgut BBMV of Plutella xylostella than Cry1Ab toxin, competes with Cry1Ab and Cry1Ac toxins for binding the midgut BBMV of Plutella xylostella, and is a mimic of Cry1Ab and Cry1Ac toxins. Through Plutella xylostella indoor insecticidal biological activity assay, the insecticidal protein shows a good insecticidal effect, and can effectively replace Cry1Ac or Cry1Ab toxin for biological control of insect pest.
PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS
Chimera proteins includlng: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.
Treatment of otitis media
A method of treating otitis media in a subject is described that includes administering to the subject a therapeutically effective amount of an Actin-Related Protein 2/3 Complex (Arp2/3) inhibitor. The role of Arp2/3 in otitis media was identified using comprehensive proteomic and metabolomic studies of otitis media using the chinchilla model.
Proteins used for the diagnosis of lyme borreliosis
Chimera proteins including: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.
Human-derived insect-resistant gene and anti-CRY1B toxin idiotype single-chain antibody encoded thereby and application thereof
Provided are a human-derived insect-resistant gene having a nucleotide sequence represented by SEQ ID NO.1, and an anti-Cry1B toxin idiotype single-chain antibody encoded by said human-derived insect-resistant gene and having an amino acid sequence represented by SEQ ID NO.2. The idiotype single-chain antibody is a -type and has insecticidal activity, and after expression by the prokaryotic system, the primary culture thereof has binding activity to Cnaphalocrocis medinalis midgut peritrophic membrane specific receptor BBMV.
Human-derived insect-resistant gene and anti-Cry1B toxin idiotype single-chain antibody encoded thereby and application thereof
An anthropogenic pest-resistant gene having a nucleotide sequence as represented by SEQ IN NO. 1, and, an anti-Cry1Ab toxin idiotypic single-chain antibody encoded by the anthropogenic pest-resistant gene and having a nucleotide sequence as represented by SEQ IN NO. 2.